THE UNIQUE ASPECTS OF ACUTE PROMYELOCYTIC LEUKEMIA

被引:152
作者
STONE, RM
MAYER, RJ
机构
[1] Dana-Farber Cancer Institute, Boston, MA
[2] Dana-Farber Cancer Institute, Boston, MA 02115
关键词
D O I
10.1200/JCO.1990.8.11.1913
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Acute promyelocytic leukemia (APL) accounts for approximately 10% of cases of acute myeloid leukemia (AML). Distinctive features of this disorder at the time of diagnosis include leukopenia coexisting with a marrow replaced with granulated dysplastic promyelocytes, disseminated intravascular coagulopathy, lack of la (HLA-DR) antigen expression, and translocation between the long arms of chromosomes 15 and 17 (t[15;17]). Heparin is widely but not universally used to interfere with the coagulopathy during the initial phases of treatment. Serial bone marrow examinations during the induction period demonstrate the achievement of remission despite the persistence of malignant-appearing promyelocytes. Patients with APL are generally younger than those with other subtypes of AML, have a 70% to 80% likelihood of entering remission, and are thought to have a more favorable prognosis than other individuals with AML. Remission may be achieved with a conventional anthracycline-cytarabine combination, anthracycline alone, or, apparently, all-trans retinoic acid. Genes potentially important in myeloid differentiation such as granulocyte colony-stimulating factor (G-CSF) and myeloperoxidase are located close to the breakpoint in the t(15;17) but have not been conclusively shown to be rearranged in the translocation. A better under-standing of the unique aspects of APL may well shed light on the pathogenetic processes of AML. © 1990 by American Society of Clinical Oncology.
引用
收藏
页码:1913 / 1921
页数:9
相关论文
共 108 条
  • [61] A CHARACTERISTIC PATTERN OF LEUKEMIC-CELL DIFFERENTIATION WITHOUT CYTOREDUCTION DURING REMISSION INDUCTION IN ACUTE PROMYELOCYTIC LEUKEMIA
    KANTARJIAN, HM
    KEATING, MJ
    MCCREDIE, KB
    BERAN, M
    WALTERS, R
    DALTON, WT
    HITTLEMAN, W
    FREIREICH, EJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (06) : 793 - 798
  • [62] KEATING MJ, 1988, LEUKEMIA, V2, P403
  • [63] KERNE TJ, 1976, ACTA HAEMATOL, V56, P202
  • [64] KINGSLEY EC, 1987, WESTERN J MED, V146, P322
  • [65] OXYGEN-METABOLISM AND THE TOXIC PROPERTIES OF PHAGOCYTES
    KLEBANOFF, SJ
    [J]. ANNALS OF INTERNAL MEDICINE, 1980, 93 (03) : 480 - 489
  • [66] KOEFFLER HP, 1983, BLOOD, V62, P709
  • [67] KOEFFLER HP, 1988, BLOOD, V71, P703
  • [68] AN ALTERATION OF THE HUMAN C-ABL PROTEIN IN K562 LEUKEMIA-CELLS UNMASKS ASSOCIATED TYROSINE KINASE-ACTIVITY
    KONOPKA, JB
    WATANABE, SM
    WITTE, ON
    [J]. CELL, 1984, 37 (03) : 1035 - 1042
  • [69] EVIDENCE FOR A 15-17 TRANSLOCATION IN EVERY PATIENT WITH ACUTE PROMYELOCYTIC LEUKEMIA
    LARSON, RA
    KONDO, K
    VARDIMAN, JW
    BUTLER, AE
    GOLOMB, HM
    ROWLEY, JD
    [J]. AMERICAN JOURNAL OF MEDICINE, 1984, 76 (05) : 827 - 841
  • [70] MAYER RJ, 1987, SEMIN ONCOL, V14, P25